Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG, a biotechnology company, was the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission. The amendment, filed on February 5, 2024, indicates that Sumitomo Mitsui Trust Holdings, Inc. (SMTH) and Nikko Asset Management Co., Ltd. (NAM), both based in Japan, have reported shared voting and dispositive power over 3,369,762 common shares of CRISPR Therapeutics, representing 4.24% of the class. The filing was made under Rule 13d-1(b), with both SMTH and NAM classified as parent holding companies and NAM additionally as an investment adviser. The shares are beneficially owned by their subsidiary, Nikko Asset Management Americas, Inc. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
CRISPR Therapeutics AG, a biotechnology company, was the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission. The amendment, filed on February 5, 2024, indicates that Sumitomo Mitsui Trust Holdings, Inc. (SMTH) and Nikko Asset Management Co., Ltd. (NAM), both based in Japan, have reported shared voting and dispositive power over 3,369,762 common shares of CRISPR Therapeutics, representing 4.24% of the class. The filing was made under Rule 13d-1(b), with both SMTH and NAM classified as parent holding companies and NAM additionally as an investment adviser. The shares are beneficially owned by their subsidiary, Nikko Asset Management Americas, Inc. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
生物技術公司CRISPR Therapeutics AG是最近向美國證券交易委員會提交的附表13G/A文件的主題。該修正案於2024年2月5日提交，表明總部位於日本的三井住友信託控股有限公司（SMTH）和日興資產管理有限公司（NAM）已報告了對CRISPR Therapeutics的3,369,762股普通股的共享投票權和處置權，佔該類別的4.24％。該文件是根據第13d-1（b）條提交的，SMTH和NAM均被歸類爲母控股公司，NAM另外被歸類爲投資顧問。這些股份由其子公司日興資產管理美洲公司實益持有。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響CRISPR Therapeutics的控制權。
生物技術公司CRISPR Therapeutics AG是最近向美國證券交易委員會提交的附表13G/A文件的主題。該修正案於2024年2月5日提交，表明總部位於日本的三井住友信託控股有限公司（SMTH）和日興資產管理有限公司（NAM）已報告了對CRISPR Therapeutics的3,369,762股普通股的共享投票權和處置權，佔該類別的4.24％。該文件是根據第13d-1（b）條提交的，SMTH和NAM均被歸類爲母控股公司，NAM另外被歸類爲投資顧問。這些股份由其子公司日興資產管理美洲公司實益持有。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響CRISPR Therapeutics的控制權。
有用
沒用